What does digital technology really mean for breast screening?
This article was originally published in Clinica
Have the high hopes for digital mammography dwindled following its rather lacklustre entry into the breast cancer screening arena? Current opinion indicates that while the technology has found some detractors, some uphold the notion that the technology could be here to stay. Robin Skelding reports
You may also be interested in...
US FDA usually recommends using overall survival for pancreatic cancer drugs, but AstraZeneca choose progression-free survival; now ODAC will weigh in on whether the PARP inhibitor olaparib demonstrated a clinically meaningful impact. The firm cites enrollment and design challenges in the gBRCAm population as reasons for using PFS.
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.